Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
India
· Delayed Price · Currency is INR 3,353.70
+31.30 (0.94%)
Jul 9, 2025, 3:29 PM IST
Torrent Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| 115,161 | 107,278 | 96,202 | 85,080 | 80,046 | Upgrade
| |
Revenue Growth (YoY) | 7.35% | 11.51% | 13.07% | 6.29% | 0.82% | Upgrade
|
Cost of Revenue | 27,759 | 26,862 | 27,352 | 24,420 | 21,464 | Upgrade
|
Gross Profit | 87,402 | 80,416 | 68,850 | 60,660 | 58,582 | Upgrade
|
Selling, General & Admin | 22,708 | 20,166 | 17,052 | 15,483 | 14,597 | Upgrade
|
Other Operating Expenses | 27,484 | 26,573 | 23,377 | 20,865 | 19,184 | Upgrade
|
Operating Expenses | 58,141 | 54,693 | 47,449 | 42,967 | 40,354 | Upgrade
|
Operating Income | 29,261 | 25,724 | 21,400 | 17,693 | 18,228 | Upgrade
|
Interest Expense | -2,514 | -3,526 | -3,322 | -2,529 | -3,508 | Upgrade
|
Interest & Investment Income | 201.9 | 114.8 | 147.8 | 71.5 | 50.7 | Upgrade
|
Currency Exchange Gain (Loss) | -166.1 | -39.1 | -180.8 | 1,695 | 319.7 | Upgrade
|
Other Non Operating Income (Expenses) | 6.9 | 314.4 | 61.1 | 76 | 21.7 | Upgrade
|
EBT Excluding Unusual Items | 26,790 | 22,587 | 18,106 | 17,007 | 15,112 | Upgrade
|
Merger & Restructuring Charges | - | - | - | -4,847 | - | Upgrade
|
Gain (Loss) on Sale of Investments | 167.3 | 179.9 | 195.1 | 101.4 | 155.8 | Upgrade
|
Gain (Loss) on Sale of Assets | 13.4 | -0.2 | 216.2 | - | - | Upgrade
|
Asset Writedown | - | -129.7 | -45.6 | -2.3 | -4.8 | Upgrade
|
Other Unusual Items | -242.1 | 883.8 | - | - | - | Upgrade
|
Pretax Income | 26,728 | 23,521 | 18,472 | 12,259 | 15,263 | Upgrade
|
Income Tax Expense | 7,616 | 6,957 | 6,019 | 4,487 | 2,744 | Upgrade
|
Earnings From Continuing Operations | 19,113 | 16,564 | 12,452 | 7,772 | 12,519 | Upgrade
|
Net Income | 19,113 | 16,564 | 12,452 | 7,772 | 12,519 | Upgrade
|
Net Income to Common | 19,113 | 16,564 | 12,452 | 7,772 | 12,519 | Upgrade
|
Net Income Growth | 15.39% | 33.02% | 60.22% | -37.92% | 22.17% | Upgrade
|
Shares Outstanding (Basic) | 338 | 338 | 338 | 338 | 338 | Upgrade
|
Shares Outstanding (Diluted) | 338 | 338 | 338 | 338 | 338 | Upgrade
|
EPS (Basic) | 56.47 | 48.94 | 36.79 | 22.96 | 36.99 | Upgrade
|
EPS (Diluted) | 56.47 | 48.94 | 36.79 | 22.96 | 36.99 | Upgrade
|
EPS Growth | 15.39% | 33.02% | 60.22% | -37.92% | 22.17% | Upgrade
|
Free Cash Flow | 19,732 | 28,333 | 17,942 | 16,004 | 16,702 | Upgrade
|
Free Cash Flow Per Share | 58.30 | 83.72 | 53.01 | 47.29 | 49.35 | Upgrade
|
Dividend Per Share | 32.000 | 28.000 | 22.000 | 16.500 | 17.500 | Upgrade
|
Dividend Growth | 14.29% | 27.27% | 33.33% | -5.71% | 105.88% | Upgrade
|
Gross Margin | 75.89% | 74.96% | 71.57% | 71.30% | 73.19% | Upgrade
|
Operating Margin | 25.41% | 23.98% | 22.25% | 20.80% | 22.77% | Upgrade
|
Profit Margin | 16.60% | 15.44% | 12.94% | 9.13% | 15.64% | Upgrade
|
Free Cash Flow Margin | 17.14% | 26.41% | 18.65% | 18.81% | 20.87% | Upgrade
|
EBITDA | 36,758 | 33,249 | 28,026 | 23,823 | 24,291 | Upgrade
|
EBITDA Margin | 31.92% | 30.99% | 29.13% | 28.00% | 30.35% | Upgrade
|
D&A For EBITDA | 7,498 | 7,526 | 6,626 | 6,130 | 6,063 | Upgrade
|
EBIT | 29,261 | 25,724 | 21,400 | 17,693 | 18,228 | Upgrade
|
EBIT Margin | 25.41% | 23.98% | 22.25% | 20.80% | 22.77% | Upgrade
|
Effective Tax Rate | 28.49% | 29.58% | 32.59% | 36.60% | 17.98% | Upgrade
|
Revenue as Reported | 115,394 | 107,858 | 96,653 | 87,046 | 80,615 | Upgrade
|
Updated Jan 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.